Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP)
- 24 May 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (11) , 4611-4625
Abstract
XIAP and cIAP1 are members of the inhibitor of apoptosis protein (IAP) family and are key regulators of anti-apoptotic and pro-survival signaling pathways. Overexpression of IAPs occurs in various cancers and has been associated with tumor progression and resistance to treatment. Structure-based drug design (SBDD) guided by structural information from X-ray crystallography, computational studies, and NMR solution conformational analysis was successfully applied to a fragment-derived lead resulting in AT-IAP, a potent, orally bioavailable, dual antagonist of XIAP and cIAP1 and a structurally novel chemical probe for IAP biology.Keywords
This publication has 32 references indexed in Scilit:
- Small-molecule SMAC mimetics as new cancer therapeuticsPharmacology & Therapeutics, 2014
- IAP proteins as targets for drug development in oncologyOncoTargets and Therapy, 2013
- Targeting IAP proteins for therapeutic intervention in cancerNature Reviews Drug Discovery, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The inhibitors of apoptosis (IAPs) as cancer targetsApoptosis, 2007
- IAPs, RINGs and ubiquitylationNature Reviews Molecular Cell Biology, 2005
- XIAP inhibits caspase‐3 and ‐7 using two binding sites: evolutionarily conserved mechanism of IAPsThe EMBO Journal, 2005
- Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell deathOncogene, 2000
- Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP InhibitionCell, 2000
- IAP family proteins---suppressors of apoptosisGenes & Development, 1999